An evaluation of prognostic factors in uterine carcinosarcoma

Gynecologic Oncology

Volumn 67, Issue 3, 1997, Pages 316-321

  Nordal, Randi R ^a   Kristensen, Gunnar B ^a   Stenwig, Anne Elisabeth ^a   Nesland, Jahn M ^a   Pettersen, Erik O ^a   Trope, Claes G ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DNA CONTENT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOSIS INDEX; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; UTERUS CARCINOMA; UTERUS SARCOMA;

EID: 0031455206     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4875     Document Type: Article

References (37)

1. 1. Harlow BL, Weiss NS, Lofton S: The epidemiology of sarcomas of the uterus, J Natl Cancer Inst 76:399-402, 1986
2. 2. Gompel S, Silverberg SG: Pathology in Gynecology and Obstetrics. 3rd ed. Philadelphia, Lippincott, 1985, pp 249-260
3. 3. Olàh KS, Dunn JA, Gee H: Leiomyosarcomas have a poorer prognosis than mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol 99:590-594, 1992
4. 4. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ: Histological typing of female genital tract tumours. 2nd ed. World Health Organization. Berlin, Springer-Verlag, 1994
5. 5. Kempson RL, Bari W: Uterine sarcomas. Classification, diagnosis and prognosis. Hum Pathology 1:331-349, 1970
6. 6. Salazar OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein M, Dunne ME, Rudolph J: Uterine sarcomas. Natural history, treatment, and prognosis. Cancer 42:1152-1160, 1978
7. 7. Wheelock JB, Krebs HB, Schneider V, Goplerud DR: Uterine sarcoma: analysis of prognostic variables in 71 cases. Am J Obstet Gynecol 151: 1016-1022, 1985
8. 8. Marchese MJ, Liskow AS, Crum CP, McCaffrey M, Frick II FC: Uterine sarcomas: a clinicopathologic study, 1965-1981. Gynecol Oncol 18:299-312, 1984
9. 9. Bokhman JV, Yakovleva IA, Urmanchejeva AF: Treatment of patients with sarcoma of the uterus. Eur J Gynecol Oncol 3:225-231, 1990
10. 10. Wolfson AH, Wolfson DJ, Sittler SY, Breton L, Markoe AM, Schwande JG, et al: A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 52: 56-62, 1994
11. 11. Norris HJ, Roth E, Taylor HB: Mesenchymal tumors of the uterus. II. A clinical pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol 28:57-63, 1966
12. 12. Norris HJ, Taylor HB: Mesenchymal tumors of the uterus. III. A clinical and pathologic study of 31 carcinosarcomas. Cancer 19:1459-1465, 1966
13. 13. Peters WA III, Kumar NB, Fleming WP, Morley GW: Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol 63:550-556, 1984
14. 14. Spanos WJ Jr, Wharton JT, Gomez L, Fletcher GH, Oswald MJ: Malignant mixed mullerian tumors of the uterus. Cancer 53:311-316, 1984
15. 15. Larson B, Silfversward C, Petterson F: Mixed Mullerian tumours of the uterus-prognostic factors. A clinical and histiopathologic study of 147 cases. Radiother Oncol 17:123-132, 1990
16. 16. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liano SY, Miller A: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. Int J Gynecol Pathol 9:1-19, 1990
17. 17. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E, Brady MF: Prognostic factors in early-stage uterine sarcoma. Cancer 4:1702-1709, 1993
18. 18. Hedley DW: Flow cytometry using paraffin-embedded tissue: Five years on. Cytometry 10:229-241, 1989
19. 19. Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO: DNA-ploidy; the most important prognostic factor in patients with borderline tumors of ovary. Int J Gynecol Cancer 3:349-358, 1993
20. 20. Nelson KG, Haskill JS, Siegfried JM, Siegal GP, Walton L, Kaufman DG: Flow cytometric analysis of human uterine sarcomas and cell lines. Cancer Res 47:2814-2820, 1987
21. 21. Malmstrøm H, Schmidt H, Persson PG, Carstensen J, Nordenskjøld B, Simonsen E: Flow cytometric analysis of uterine sarcoma: Ploidy and S-phase rate as prognostic indicators. Gynecol Oncol 44:172-179, 1992
22. 22. Kjellberg L, Boquist L, Stendahl U, Tribukait B: Flow cytometric analysis of uterine sarcomas. Gynecol Oncol 55:339-342, 1994
23. 23. Peters WA, Howard DR, Andersen WA, Figge DC: Deoxyribonucleic acid analysis by flow cytometry of uterine leiomyosarcomas and smooth muscle tumors of uncertain malignant potential. Am J Obstet Gynecol 166: 1646-1654, 1992
24. 24. Nordal RR, Kristensen GB, Kaern J, Stenwig, AE, Pettersen EO, Trope CG: The prognostic significance of stage, tumor size, cellular atypia and ploidy in uterine leiomyosarcoma. Acta Oncol 34:797-802, 1995
25. 25. Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Trope CG: The prognostic significance of surgery, tumor size, malignancy grade, menopausal status and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol 62:254-259, 1996
26. 26. International Federation of Gynecology and Obstetrics. Annual Report on the Treatment in Gynecologic Cancer. Stockholm, International Federation of Gynecology and Obstetrics. 1985, p 19
27. 27. Angervall L, Kindblom LG: Principles for the pathologic diagnosis of soft tissue sarcomas. Acta Oncol 28:9-17, 1989
28. 28. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Methods for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333-1335, 1983
29. 29. Kaern J, Trope C, Kjørstad KE, Abeler V, Pettersen EO: Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 38:452-457, 1990
30. 30. Hiddemann W, Schumann J, Andreff M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF, Sandberg AA: Convention on nomenclature for DNA Cytometry. Cytometry 5:445-446, 1984
31. 31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
32. 32. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
33. 33. Abeler VM, Kjørstad KE, Nesland JM: Undifferentiated carcinoma of the endometrium. A histopathological study of 31 cases. Cancer 68:98-105, 1991
34. 34. Evans HL: Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 50:2170-2182, 1982
35. 35. Nordal RR, Kjørstad KE, Stenwig AE, Trope CT: Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976-1985. Int J Gynecol Cancer 3:110-115, 1993
36. 36. Marth C, Windbichler G, Petru E, Dirschlmayer W, Obermaier A, Czerwenka K, Müller-Holzner E, Dapunt O: Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium. Gynecol Oncol 64:121-125, 1997
37. 37. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma in Norway; A study of a total population. Cancer 67:3093-3103, 1991